Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary AMARIN CORP IS FIRST SMALL BIOPHARMACEUTICAL COMPANY TO JOIN SAFE-BIOPHARMA ASSOCIATION
AMARIN CORP IS FIRST SMALL BIOPHARMACEUTICAL COMPANY TO JOIN SAFE-BIOPHARMA ASSOCIATION Ft. Lee, N.J. (November 11, 2009) – Amarin Corp .(NASDAQ: AMRN), a clinical stage pharmaceutical company with R&D operations based in Mystic, Conn., has joined SAFE-BioPharma Association , the non-profit
View HTML
Toggle Summary AMARIN APPOINTS JOHN F. THERO AS CHIEF FINANCIAL OFFICER
AMARIN APPOINTS JOHN F. THERO AS CHIEF FINANCIAL OFFICER DUBLIN, Ireland, November 6th, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced the appointment of John F. Thero as the Company’s Chief Financial Officer. In this role, Mr. Thero will have broad responsibility for financial and
View HTML
Toggle Summary AMARIN ANNOUNCES COMPLETION OF $70 MILLION PRIVATE PLACEMENT
AMARIN ANNOUNCES COMPLETION OF $70 MILLION PRIVATE PLACEMENT AMARIN ANNOUNCES COMPLETION OF $70 MILLION PRIVATE PLACEMENT DUBLIN, Ireland, October 19, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced it has closed its $70 million private placement.
View HTML
Toggle Summary AMARIN APPOINTS MEDPACE AS CRO FOR TWO PHASE 3 CARDIOVASCULAR TRIALS
AMARIN APPOINTS MEDPACE AS CRO FOR TWO PHASE 3 CARDIOVASCULAR TRIALS DUBLIN, Ireland, October 19, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has executed an agreement with Medpace, Inc. (‘Medpace’), a leading Contract Research Organization (CRO) with expertise in
View HTML
Toggle Summary AMARIN ANNOUNCES CHANGES TO ITS BOARD AND MANAGEMENT TEAM
AMARIN ANNOUNCES CHANGES TO ITS BOARD AND MANAGEMENT TEAM AMARIN ANNOUNCES CHANGES TO ITS BOARD AND MANAGEMENT TEAM DUBLIN, Ireland, October 13, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced changes to its board and management team, in conjunction with its separately announced $70
View HTML
Toggle Summary AMARIN ANNOUNCES $70 MILLION PRIVATE PLACEMENT
AMARIN ANNOUNCES $70 MILLION PRIVATE PLACEMENT DUBLIN, Ireland, October 13, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced it has entered into a definitive agreement with several existing and new institutional and accredited investors for a $70 million private placement.
View HTML
Toggle Summary AMARIN RECEIVES EXTENSION FROM NASDAQ TO FILE ITS 2008 ANNUAL REPORT ON FORM 20-F
AMARIN RECEIVES EXTENSION FROM NASDAQ TO FILE ITS 2008 ANNUAL REPORT ON FORM 20-F DUBLIN, Ireland, October 5, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that Nasdaq has granted the Company’s requested extension to the deadline to file its 2008 Annual Report on Form 20-F with the
View HTML
Toggle Summary AMARIN ANNOUNCES EXTENSION TO BRIDGE FINANCING
AMARIN ANNOUNCES EXTENSION TO BRIDGE FINANCING DUBLIN, Ireland, October 1, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has reached an agreement with the lenders of the Company’s $5.5 million bridge financing to extend the maturity date to October 16, 2009.
View HTML
Toggle Summary AMARIN ANNOUNCES $3.0 MILLION BRIDGE FINANCING
AMARIN ANNOUNCES $3.0 MILLION BRIDGE FINANCING DUBLIN, Ireland, August 3, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has executed an agreement for the private placement of convertible bridge loan notes (“Bridge Financing”) in the amount of $3.0 million with select
View HTML
Toggle Summary Amarin Receives Special Protocol Assessment Agreement From The FDA For Phase 3 Trial In Mixed Dyslipidemia
Amarin Receives Special Protocol Assessment Agreement From The FDA For Phase 3 Trial In Mixed Dyslipidemia DUBLIN, Ireland, July 9, 2009 – Amarin Corporation plc (NASDAQ: AMRN) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol
View HTML
copyright
© 2018, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation